Overview

Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma

Status:
Unknown status

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) combination is considered as the new gold standard for the first-line treatment of elderly patients with diffuse large B-cell lymphoma (DLBCL). The study is aimed to evaluate the overall response rate and the safety of four cycles of R-CHOP chemotherapy and followed by rituximab augmentation (weekly four times infusion) in newly diagnosed DLBCL patients with aged more than 70 years.

Phase:

Phase 2

Details

Lead Sponsor:

Chonnam National University Hospital

Collaborators:

Asan Medical Center
Samsung Medical Center
Severance Hospital

Treatments:

Rituximab